Patents Issued in April 18, 2019
  • Publication number: 20190110988
    Abstract: The present invention discloses a liposomal delivery vehicle that includes lignite extract (or humic or fulvic acid) as a complexing agent to improve the stability and ultradeformability of the liposomal vehicle, thereby improving bioavailability. An emulsion delivery vehicle that includes lignite extract (or humic or fulvic acid) as the complexing agent is also disclosed. These improved delivery vehicles enhance the pharmacokinetic profiles of the active ingredients and reduce the quantities needs for therapeutic effect.
    Type: Application
    Filed: October 17, 2017
    Publication date: April 18, 2019
    Applicant: Lemulsa Technologies Inc.
    Inventors: Tyler Barrett, Charles Sly
  • Publication number: 20190110989
    Abstract: Systems and methods for producing liposomes, including control liposomes and immunoliposomes targeting breast cancer are provided. Systems and methods for treating breast cancer, using targeted immunoliposomes produced according to various methods are also disclosed herein. For example, trastuzumab-conjugated immunoliposomes may be used to deliver chemotherapeutic agents to breast cancer tissues for the treatment of breast cancer. Systems and methods for actuating liposomes using ultrasound are also disclosed, such as systems and methods for actuating trastuzumab-conjugated liposomes accumulated in breast cancer tissues for the treatment of breast cancer.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 18, 2019
    Inventors: Ghaleb Husseini, Mohammad Al-Sayah, Amal Elsadig
  • Publication number: 20190110990
    Abstract: The present invention relates to lipoproteins containing platinum complex. The invention also relates to a kit comprising said lipoproteins. In particular, the present invention relates to the use of said platinum-complex-bearing lipoproteins for the specific targeting of macrophages and tumour cells in the treatment of cancer.
    Type: Application
    Filed: May 29, 2017
    Publication date: April 18, 2019
    Inventors: Frédéric LIRUSSI, Carmen GARRIDO-FLEURY, Laurent LAGROST
  • Publication number: 20190110991
    Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).
    Type: Application
    Filed: September 10, 2018
    Publication date: April 18, 2019
    Inventors: Mark E. HAYES, Charles O. NOBLE, Francis C. SZOKA, JR.
  • Publication number: 20190110992
    Abstract: The invention relates to a pharmaceutical dosage form for oral administration comprising a pharmacologically active compound; wherein a portion of said pharmacologically active compound is contained in a multitude of immediate release particles providing immediate release of the pharmacologically active compound; wherein another portion of said pharmacologically active compound is contained in at least one controlled release particle providing controlled release of the pharmacologically active compound; and wherein the breaking strength of each of the immediate release particles and/or of the at least one controlled release particle is at least 300 N.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 18, 2019
    Applicant: Grünenthal GmbH
    Inventors: Carmen Stomberg, Harald Paul, Klaus Wening, Sebastian Schwier
  • Publication number: 20190110993
    Abstract: The present invention provides pharmaceutical compositions composed of solid nanoparticles dispersed in aqueous medium of substantially water insoluble pharmaceutical substances with reduced Ostwald ripening.
    Type: Application
    Filed: September 12, 2018
    Publication date: April 18, 2019
    Inventors: Raj Selvaraj, Chandra U. Singh, David L. Woody
  • Publication number: 20190110994
    Abstract: Present invention discloses the stable pharmaceutical composition comprising premix of dapagliflozin with at least one pharmaceutically acceptable excipient(s) and process for preparation thereof. Dapagliflozin is highly hygroscopic and hence it is difficult to formulate dapagliflozin as stable pharmaceutical composition. Present invention discloses the stable pharmaceutical composition of dapagliflozin comprising premix of dapagliflozin with lactose.
    Type: Application
    Filed: March 30, 2017
    Publication date: April 18, 2019
    Applicant: LUPIN LIMITED
    Inventors: Chandrakant SHERVI, Byomakesh PANDA, Murali Krishna BHAVARISETTI, Subhasis DAS, Vijaya Kumar THOMMANDRU
  • Publication number: 20190110995
    Abstract: The present invention relates to a pharmaceutical composition, particularly a modified release tablet composition comprising mirabegron or a pharmaceutically acceptable salt thereof and to a process for preparing such a composition
    Type: Application
    Filed: October 12, 2017
    Publication date: April 18, 2019
    Inventors: Agnes FERNANDEZ PENA, Onne Peter Hilbert BACKERS, Jose VELADA CALZADA
  • Publication number: 20190110996
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: October 17, 2018
    Publication date: April 18, 2019
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Publication number: 20190110997
    Abstract: The invention relates to an oral administration form which comprises at least one species of probiotic microorganisms, where it itself and/or the probiotic bacteria is/are provided with a coating which comprises at least two cellulose ethers.
    Type: Application
    Filed: November 16, 2018
    Publication date: April 18, 2019
    Applicant: Merck Patent GmbH
    Inventors: Markus RUDOLPH, Stefan HENKE, Iris MANNECK
  • Publication number: 20190110998
    Abstract: An object of the present invention is to provide a particulate composition for an easy-to-take solid preparation, which has excellent moldability (hardness) and slipperiness. The present invention relates to a particulate composition for an easy-to-take solid preparation, comprising sugar alcohol and a gelling agent that will show slipperiness when it is brought into contact with water, wherein a part or whole of the surface of the particulate composition is coated with the gelling agent, to an easy-to-take solid preparation comprising the particulate composition, and to a method for the production of the easy-to-take solid preparation.
    Type: Application
    Filed: September 21, 2016
    Publication date: April 18, 2019
    Inventors: Momoko HAMASAKI, Tomohito OKABAYASHI, Anan SAKAGUCHI, Takahiro HIRAMURA
  • Publication number: 20190110999
    Abstract: An artificial device, method and system are provided for the manufacture and use of artificial nanospheres, enclosed resins, and similar technologies for sequestering lipophilic molecules from environments, such as a gastrointestinal tract.
    Type: Application
    Filed: October 13, 2017
    Publication date: April 18, 2019
    Inventor: Jacob Jennings Orme
  • Publication number: 20190111000
    Abstract: Multistage delivery vehicles are disclosed which include a first stage particle and a second stage particle. The first stage particle is a micro or nanoparticle that contains the second stage particle. The second stage particle includes an active agent, such as a therapeutic agent or an imaging agent. The multistage delivery vehicle allows sequential overcoming or bypassing of biological barriers. The multistage delivery vehicle is administered as a part of a composition that includes a plurality of the vehicles. Methods of making the multistage delivery vehicles are also provided.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 18, 2019
    Applicants: Board of Regents of the University of Texas System, The Ohio State University Research Foundation
    Inventors: Mauro Ferrari, Ennio Tasciotti, Jason Sakamoto
  • Publication number: 20190111001
    Abstract: A delivery system that allows for targeted released of therapeutics in selected regions of the GI tract is provided. The delivery system is adapted to deliver a certain type of therapeutic, such as a protein-based therapeutic, to a certain area of the GI tract, such the colon of a subject. The delivery vehicle comprises a microbead coated with layers that include: a subcoat layer and a therapeutic agent layer. The delivery vehicles may also include an enteric coating layer and/or a sustained release layer.
    Type: Application
    Filed: March 30, 2017
    Publication date: April 18, 2019
    Applicant: University of Maryland, Baltimore
    Inventors: Hanping FENG, Hua YU, Stephen HOAG, Bowen JIANG
  • Publication number: 20190111002
    Abstract: The invention relates to a nanoparticle comprising: (i) between 60 wt.-% and 99 wt.-% sorbitan ester, relative to the total weight of the nanoparticle; (ii) a positively charged substance; and (iii) a miRNA. The invention also relates to the methods for producing same and to the uses thereof, particularly for therapeutic uses, such as cancer treatment.
    Type: Application
    Filed: April 4, 2017
    Publication date: April 18, 2019
    Applicant: UNIVERSIDADE DE SANTIAGO DE COMPOSTELA
    Inventors: Alejandro SÁNCHEZ BARREIRO, Inés FERNÁNDEZ PIÑEIRO, Iker BADIOLA, Joana MÁRQUEZ
  • Publication number: 20190111003
    Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36? (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
    Type: Application
    Filed: December 20, 2018
    Publication date: April 18, 2019
    Inventors: Joshua FREDERICK, Ailin BAI, Vladimir PRESNYAK, Stephen HOGE, Kerry BENENATO, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Susannah HEWITT
  • Publication number: 20190111004
    Abstract: The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles.
    Type: Application
    Filed: September 7, 2018
    Publication date: April 18, 2019
    Applicant: Pfizer Inc.
    Inventors: Maria Figueiredo, Erick Peeke, David Dewitt, Christina Van Geen Hoven, Greg Troiano, James Wright, Yong-ho Song, Hong Wang
  • Publication number: 20190111005
    Abstract: The present technology relates generally to devices for treatment of skin and skin conditions, as well as methods for preparing the devices and methods of treatment using the devices. Suitably, the devices comprise a hydrocolloid dressing and one or more active agents, wherein the amount of the active agent(s) does not reduce the absorption properties of the hydrocolloid dressing.
    Type: Application
    Filed: October 15, 2018
    Publication date: April 18, 2019
    Inventor: Enrico FREZZA
  • Publication number: 20190111006
    Abstract: A method of preserving the one or more chemical and/or biological species in a polymer matrix comprising pullulan and trehalose is described. The method includes combining the one or more chemical and/or biological species, an aqueous pullulan and a trehalose solution and drying the resultant mixture to provide a solid polymeric matrix. A polymeric matrix comprising one or more chemical and/or biological species and its use, for example, on surfaces for food preparation, for food preservation and in biological preparations is also described.
    Type: Application
    Filed: October 16, 2018
    Publication date: April 18, 2019
    Applicant: McMaster University
    Inventors: Vincent Ho Yin Leung, Sana Jahanshahi- Anbuhi, Carlos Filipe, M. Monsur Ali
  • Publication number: 20190111007
    Abstract: Provided are inhibitors of sphingosine kinase Type I and their use in the treatment of asthma, among other indications and diseases.
    Type: Application
    Filed: November 26, 2018
    Publication date: April 18, 2019
    Applicants: Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc., Virginia Commonwealth University
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • Publication number: 20190111008
    Abstract: Methods of storing and methods of stabilizing pharmaceutical compositions comprising cysteamine, or a pharmaceutically acceptable salt thereof, are provided. Methods of distributing pharmaceutical compositions comprising cysteamine, or a pharmaceutically acceptable salt thereof, and methods of treating cystinosis also are provided.
    Type: Application
    Filed: November 19, 2018
    Publication date: April 18, 2019
    Inventors: Michael DESJARDIN, Mark JOHNSON
  • Publication number: 20190111009
    Abstract: Methods and compositions comprising N-acetylcysteine amide (NAC amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of NAC amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce, prevent, or counteract oxidative stress and free radical oxidant formation and overproduction in cells and tissues, as well as to provide a new source of glutathione.
    Type: Application
    Filed: April 2, 2018
    Publication date: April 18, 2019
    Inventor: Glenn A. Goldstein
  • Publication number: 20190111010
    Abstract: This invention relates to the treatment of breast cancer in a subject, for example a female subject.
    Type: Application
    Filed: July 31, 2018
    Publication date: April 18, 2019
    Applicant: GTX, INC.
    Inventors: Ramesh NARAYANAN, Thamarai PONNUSAMY
  • Publication number: 20190111011
    Abstract: There is provided herein a pharmaceutical formulation having one or more component comprising valproic acid (VPA) and/or a pharmaceutically acceptable salt thereof; and one or more secondary acid, and optionally comprising one or more pharmaceutically acceptable excipient. There is also provided uses of such formulations.
    Type: Application
    Filed: April 10, 2017
    Publication date: April 18, 2019
    Inventors: Nils Ove Gustafsson, Hans Martensson, Niklas Bergh, Jonas Faijerson Saljo, Sverker Jem
  • Publication number: 20190111012
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethyl-methyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Application
    Filed: March 30, 2017
    Publication date: April 18, 2019
    Inventor: Rémy Hanf
  • Publication number: 20190111013
    Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Application
    Filed: December 6, 2018
    Publication date: April 18, 2019
    Applicant: Osmotica Kereskedelmi ES Szolgaltato KFT
    Inventors: Glenn A. MEYER, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
  • Publication number: 20190111014
    Abstract: A superior dual ACE/NEP inhibitor is a combination that selectively targets the ACE C-domain in addition to inhibiting NEP. Such a dual ACE C-domain/NEP inhibitor can be used in the treatment of diverse cardiovascular diseases, including hypertension and heart failure.
    Type: Application
    Filed: March 31, 2017
    Publication date: April 18, 2019
    Inventors: Edward D. STURROCK, Mario R.W. EHLERS
  • Publication number: 20190111015
    Abstract: A composition of chlorogenic acids and method of its use and manufacture in the treatment of metabolic disorders. The composition can be obtained from sunflower seed extract, including Helianthus annulus seeds.
    Type: Application
    Filed: October 11, 2018
    Publication date: April 18, 2019
    Applicant: Vidya Herbs, Inc.
    Inventor: Kodimule Shyam Prasad
  • Publication number: 20190111016
    Abstract: Provided are methods of treating muscle and liver disorders, and for increasing mitochondrial mass and/or functionality in a mammalian myocyte and/or hepatocyte.
    Type: Application
    Filed: August 23, 2018
    Publication date: April 18, 2019
    Applicant: The Regents of the University of California
    Inventors: Gino Cortopassi, Genki Hayashi
  • Publication number: 20190111017
    Abstract: The disclosure provides for a method for treating a fatty liver disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic, or has normal or substantially normal biliary tract function; and administering a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E). In some cases EPA-E present may be at least 40% by weight in total of the fatty acids and their derivatives.
    Type: Application
    Filed: December 6, 2018
    Publication date: April 18, 2019
    Inventors: Tsuyoshi Harada, Hideo Kanehiro, Kiyoshi Mizuguchi
  • Publication number: 20190111018
    Abstract: A formulation, including: (a) a first medicament, wherein the first medicament includes an isothiocyanate functional compound/surfactant; and (b) a second medicament, wherein the second medicament includes an antineoplastic agent, such as a cytotoxic antineoplastic agent and/or a targeted antineoplastic agent.
    Type: Application
    Filed: December 11, 2018
    Publication date: April 18, 2019
    Inventor: Michael E. Silver
  • Publication number: 20190111019
    Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 18, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tohru KAMBE, Toru MARUYAMA, Shinsaku YAMANE, Satoshi NAKAYAMA, Kousuke TANI
  • Publication number: 20190111020
    Abstract: Methods for the preparation of nanosized nutrient formulations for enhanced absorption of nutritional agents. The methods include the complexation of cyclodextrin with carotenoids and incorporation of the complexes into the nutritional supplements without intermediate collection, isolation, and drying steps.
    Type: Application
    Filed: April 16, 2018
    Publication date: April 18, 2019
    Applicant: NSE Products, Inc.
    Inventors: Mark Bartlett, Angela Mastaloudis, Carsten Smitdt, Stephen J. Poole
  • Publication number: 20190111021
    Abstract: The present invention disclosed a formulation in the form of self-emulsifying drug delivery formulation for improved delivery of tocotrienols comprising a fat-soluble compound, at least one emulsifier, and an oil carrier. The formulation shows an improved bioavailability of tocotrienols.
    Type: Application
    Filed: November 30, 2018
    Publication date: April 18, 2019
    Inventors: Chee Wai FONG, Yee Wei UNG, Jordan Todorov PETKOV
  • Publication number: 20190111022
    Abstract: The present invention provides a method for inhibiting growth of at least one tumor selected from the group consisting of uterine cancer, esophageal cancer, pancreatic cancer, liver cancer, biliary tract cancer, duodenal cancer, lung cancer, kidney cancer, sarcoma, brain tumor, urothelial cancer, thyroid cancer, stomach cancer, and lymphoma in a patient, by administering to the patient a liposome composition comprising eribulin or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 26, 2017
    Publication date: April 18, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Makoto Asano, Junji Matsui
  • Publication number: 20190111023
    Abstract: Uses of acyl-homoserine lactone compounds are described. In particular, uses of acyl-homoserine lactone compounds as anti-thrombotic agents, to inhibit platelets from becoming hypersensitive, and/or to prevent thrombosis, are described.
    Type: Application
    Filed: December 12, 2018
    Publication date: April 18, 2019
    Applicant: The University of Toledo
    Inventors: Randall G. Worth, Glenn R. Westphal, Brenton R. Keeley, Leah M. Wuescher
  • Publication number: 20190111024
    Abstract: A method of treating post-traumatic stress disorder is provided. The method includes administering a composition of amino acids, melatonin, and vitamins, and then tracking, through testing and the like, a progression of the treatment. Typically, but not necessarily, the composition is administered orally in the form of pills, powder, pre-mixed food items, and the like.
    Type: Application
    Filed: October 12, 2017
    Publication date: April 18, 2019
    Inventor: Juan Tejada-Duran
  • Publication number: 20190111025
    Abstract: Multi-functions Selective COX inhibitors The invention relates to a new class of compounds targeting COX-1. The invention also relates to the use of some of such compounds as a tool to investigate the structure and function of the enzyme, in the treatment targeting COX-1 or detection of COX-1 in relating disorders or diseases such as cancer and neuroinflammation, in particular in neurological (e.g. autism spectrum disorders) and neurodegenerative diseases (e.g. Alzheimer's diseases, Parkinson's diseases, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), traumatic brain injury (TBI), HIV dementia and prion diseases), and in gynecological tumour (e.g. ovarian cancer), neck and head tumor, and haematological tumours (e.g. multiple myeloma) and in the detection of COX-1 in “in vitro” (cells and tissues) and in “in vivo”.
    Type: Application
    Filed: April 26, 2017
    Publication date: April 18, 2019
    Inventors: Antonio SCILIMATI, Maria Grazia PERRONE, Paola VITALE
  • Publication number: 20190111026
    Abstract: An object of the present invention is to provide a novel anti-Tritrichomonas agent. Provided is an anti-Tritrichomonas agent containing luliconazole.
    Type: Application
    Filed: October 12, 2016
    Publication date: April 18, 2019
    Inventors: Yoshiyuki MIYATA, Takaaki MASUDA
  • Publication number: 20190111027
    Abstract: A composition for controlling or preventing microsporidia in a fish or a seafood is prepared by using, as an active ingredient, at least one compound selected from the group consisting of compounds represented by the following chemical formula (I): (wherein, R2, R4, R5, R6 and R7 each independently represent a specific substituent), pharmaceutically acceptable salts thereof, and compounds generating the compounds represented by the chemical formula (I) by metabolism in the body of the fish or the seafood. By using this composition for controlling or preventing microsporidia in a fish to or a seafood, a method for controlling or preventing microsporidia in a fish or a seafood is provided, which prevents microsporidian infection in the muscle or organs of the fish or the seafood, and/or suppresses the growth of microsporidia in the muscle or organs of the fish or the seafood, and/or highly effective in eliminating microsporidia from the body of the fish or the seafood and also excellent in safety.
    Type: Application
    Filed: March 30, 2017
    Publication date: April 18, 2019
    Applicants: MARUHA NICHIRO CORPORATION, THE UNIVERSITY OF TOKYO
    Inventors: Yukitoki FUJITA, Hiroshi YOKOYAMA, Hiroki OGAWA
  • Publication number: 20190111028
    Abstract: Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 18, 2019
    Inventors: Laszlo R. Treiber, Irina Zamansky, Jean-Luc Girardet
  • Publication number: 20190111029
    Abstract: The invention relates to the treatment of impulsivity-related disorders, such as a substance-related addiction, a behavioural addiction, relapse to a substance-related or behavioural addiction, a habit or impulsive disorder, an emotional unstable personality disorder, intentional self harm, an eating disorder, a dopamine agonist-induced impulse control disorder, or attention deficit hyperactivity disorder (ADHD) by administering a compound of Formula I or a salt thereof to a subject; Formula (I) wherein: E is S or Se; R1 and R2 are optional substituents, and are at each occurrence independently selected from: (1) a halogen, which is preferably selected from F, CI and Br; (2) C1-C4 alkyl, such as C1-C2 alkyl or C1 alkyl, optionally substituted with one or more halogen atoms, each of which is preferably selected from F, CI and Br; and (3) C1-C4 alkoxy, such as C1-C2 alkoxy or C1 alkoxy; optionally substituted with one or more halogen atoms, each of which is preferably selected from F, CI and Br; m is an integer
    Type: Application
    Filed: April 27, 2017
    Publication date: April 18, 2019
    Inventors: Robert David ROGERS, Trevor SHARP
  • Publication number: 20190111030
    Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 18, 2019
    Applicant: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, James J. Donegan, Paul Diamond
  • Publication number: 20190111031
    Abstract: Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.
    Type: Application
    Filed: March 15, 2017
    Publication date: April 18, 2019
    Inventors: Kevin Duane Bunker, Deborah Helen Slee, Chad Daniel Hopkins, Joseph Robert Pinchman, Mehmet Kahraman, Peter Qinhua Huang
  • Publication number: 20190111032
    Abstract: Described herein are compounds that can bind CaSR and/or a CaSR extracellular domain and formulations thereof. Also described herein are methods of inhibiting CaSR and/or treating a disease or disorder associated with a mutation in CaSR by administering a compound or formulation thereof described herein. Also described herein are assays that can be used to identify compounds that can bind an extracellular domain of CaSR.
    Type: Application
    Filed: March 29, 2017
    Publication date: April 18, 2019
    Inventors: Jenny Jie YANG, Jian HU, Edward BROWN, Kelley MOREMEN
  • Publication number: 20190111033
    Abstract: Methods of treating tinnitus with gaboxadol or a pharmaceutically acceptable salt thereof are provided. Also provided are therapeutic compositions that may be used to improve one or more symptoms of tinnitus. Methods of treating acute sensorineural hearing loss or Meniere's disease with gaboxadol or a pharmaceutically acceptable salt thereof are provided. Also provided are therapeutic compositions that may be used to improve one or more symptoms of acute sensorineural hearing loss or Meniere's disease.
    Type: Application
    Filed: December 12, 2018
    Publication date: April 18, 2019
    Inventor: Matthew DURING
  • Publication number: 20190111034
    Abstract: The present invention relates to the use of CDK8 and/or CDK19 inhibitors in the treatment of ribosomopathies as well as conditions characterized by reduced number of hematopoietic stem cells and/or progenitor cells; and bone anabolic disorders.
    Type: Application
    Filed: November 3, 2016
    Publication date: April 18, 2019
    Inventors: Johan FLYGARE, Lars JOHANSSON, Thomas LUNDBÄCK
  • Publication number: 20190111035
    Abstract: This invention relates to the use of low doses of (+)-?-dihydrotetrabenazine for the treatment of movement disorders, such as Tourette's syndrome.
    Type: Application
    Filed: October 4, 2018
    Publication date: April 18, 2019
    Applicant: ADEPTIO PHARMACEUTICALS LIMITED
    Inventors: Andrew John DUFFIELD, Anant PANDYA
  • Publication number: 20190111036
    Abstract: Described herein are methods of treating non-metastatic castrate-resistant prostate cancer using an approved drug product comprising apalutamide, enzalutamide or darolutamide. Also described here are drug products containing apalutamide enzalutamide or darolutamide, and methods of selling or offering for sale an anti-androgen drug product.
    Type: Application
    Filed: April 30, 2018
    Publication date: April 18, 2019
    Inventor: Arturo Molina
  • Publication number: 20190111037
    Abstract: This disclosure relates to use of certain aldehyde compounds for treating pulmonary fibrosis, hypoxia, and connective tissue and autoimmune disease such as scleroderma, lupus, arthritis and related conditions in a mammal.
    Type: Application
    Filed: May 16, 2018
    Publication date: April 18, 2019
    Inventors: Zhe Li, Jason R. Harris, Kobina N. Dufu, Xin Geng, Uma Sinha